{"url_path":"/sec/apvo/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1671584/0001193125-26-221661-index.html","accession_number":"0001193125-26-221661","cik":"0001671584","ticker":"APVO","issuer_name":"Aptevo Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1671584/0001193125-26-221661-index.html","primary_entity_key":"0001671584","primary_entity_name":"Aptevo Therapeutics Inc."},"word_count":272,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nExhibit Index\n\nExhibit\n\nNumber\n\nDescription\n\n \n\n \n\n \n\n10.1\n\n \n\n[Standby Equity Purchase Agreement, dated January 8, 2026 by and between Aptevo Therapeutics Inc. and YA II PN, LTD.](https://www.sec.gov/Archives/edgar/data/1671584/000119312526008318/apvo-ex10_1.htm) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 9, 2026).\n\n31.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002.](apvo-ex31_1.htm)\n\n \n\n \n\n \n\n31.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002.](apvo-ex31_2.htm)\n\n \n\n \n\n \n\n32.1**\n\n \n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](apvo-ex32_1.htm)\n\n \n\n \n\n \n\n32.2**\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](apvo-ex32_2.htm)\n\n \n\n \n\n \n\n101.SCH*\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n \n\n \n\n \n\n101.INS*\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n \n\n104*\n\n \n\nCover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)\n\n \n\n* Filed herewith.\n\n** Furnished herewith.\n\n \n\n55\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nAPTEVO THERAPEUTICS INC.\n\n \n\nDate: May 13, 2026\n\nBy:\n\n \n\n/s/ Jeffrey G. Lamothe\n\n \n\nJeffrey G. Lamothe\n\n \n\nPresident and Chief Executive Officer\n\n \n\n \n\nDate: May 13, 2026\n\nBy:\n\n \n\n/s/ Daphne Taylor\n\n \n\nDaphne Taylor\n\n \n\nSenior Vice President and Chief Financial Officer\n\n \n\n \n\n56"}